Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)

Aegerion Pharmaceuticals, Inc. (Aegerio) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders. As of December 31, 2011, the Company developed its first product candidate, lomitapide, as an oral, once-a-day treatment for patients with a inherited lipid disorder called homozygous familial hypercholesterolemia (HoFH). The Company conducted a 78-week Phase III clinical trial of lomitapide in the treatment of adult patients with HoFH. The 56-week results of the trial were announced in May 2011. It completed the trial during the year ended December 31, 2011, and in January 2012, announced the 78-week results of the trial, which were consistent with the 56-week results. In 2011, the United States Food and Drug Administration (FDA) granted orphan drug designation for lomitapide in the treatment of HoFH.